

Kidney Cancer GCOM 9 (day 2) minutes

Kidney Cancer update – committee meeting 9 (day 2) minutes

Date: 07/02/2025

Location: Virtual and NICE, 2 Redman Place, London, E20 1JQ

Minutes: Final

Committee members present:		
Baljit Singh	Chair	Present for items 1-7
Axel Bex	Urological Surgeon	Present for items 1-7
Amarnath Challapalli	Clinical Oncologist (General)	Present for items 1-6
Amy Clifford	Clinical Oncologist (SABR)	Present for items 1-7
John Connolly	Lay Member	Present for items 1-7
Stuart Evans	Oncology Pharmacist	Present for items 1-7
Geraldine Fox	Lay Member	Present for items 1-7
Fayiza Habeeb	Lead Nurse Practitioner	Present for items 1-7
David Mole	Nephrologist (co-opted member)	Present for items 1-7
Ankit Rao	Medical Oncologist	Present for items 1-7
Ana Semedo	Cancer Nurse Specialist (Urology)	Present for items 1-7
Sandeep Singh Randhawa	General Practitioner	Present for items 1-7
Grant Stewart	Topic Adviser	Present for items 3-5
Sam Withey	Diagnostic Radiologist	Present for items 1-7
Rose Woodward	Lay Member	Present for items 1-7

In attendance NICE:		
Marie Harrisingh	Topic Lead	Present for items 1-7
Adefisayo Abba-Abba	Technical Analyst	Present for items 1-7
Sarah Boyce	Senior Technical Analyst	Present for items 1-7
Victoria Carter	Implementation Support Manager	Present for items 1-2, 5-7
Danielle Conroy	Project Manager	Present for items 1-7
Lindsay Claxton	Health Economics Adviser	Present for items 1-7
Olivia Crane	Senior Technical Analyst	Present for items 1-7
James Hall	Senior Medical Editor	Present for items 1-6

Kidney Cancer GCOM 9 (day 2) minutes

Lina Manounah	Technical Analyst	Present for items 1-7
Agnesa Mehmeti	Technical Analyst (Observing)	Present for items 1-7
Katherine Saxby	Medicines Adviser, Medicines Optimisation	Present for items 3-4
Hannah Tebbs	Senior Health Economist	Present for items 1-7
Ellie Zachariades	Senior Guidance Content Designer (Observing)	Present for items 1-7
Yuanyuan Zhang	Senior Health Economist	Present for items 1-7

Apologies:

Janet Brown	Medical Oncologist, Committee member
Lisa Browning	Histopathologist, Committee member
David Cullen	Urology Cancer Nurse, Committee member
Maxine Tran	Urological Surgeon, Committee member
Tze Min Wah	Interventional Radiologist, Committee member

1. Welcome, Introductions and DOIs

The Chair, Baljit Singh (BS) welcomed the committee members and NICE attendees to day 2 of the 9th committee meeting for the NICE Kidney Cancer guideline.

BS informed attendees that apologies had been received as noted above. BS asked all committee members to verbally declare any new interests.

No new interests were declared and the minutes from committee 9 (day 1) were checked and agreed to be an accurate record.

2. RQ 2a(i) (CT or MRI for diagnosing renal lesions in adults with suspected renal cell carcinoma):

- **Presentation of clinical evidence**
- **Presentation of health economic evidence**
- **Health equality and inequality considerations**
- **Committee discussion**

The Chair introduced Adefisayo Abba-Abba (AA) Technical Analyst and Hannah Tebbs (Senior Health Economist) who presented the clinical and health economics evidence for CT or MRI for diagnosing renal lesions in adults with suspected renal cell carcinoma.

The committee had the opportunity to ask questions and discuss what was presented, including measuring diagnostic accuracy and the quality of the data. They

also considered any potential health equality and health inequality issues in this area.

The Chair thanked AA and HT for their presentation.

3. Draft recommendations

Taking input from the committee to draft the initial wording, the NICE team were able to draft recommendations for the use of CT and MRI for diagnosis that would be taken away for further edits.

BS thanked the committee for their input.

4. Technology appraisal incorporation overview

The Chair introduced Katherine Saxby (KS) Medicines Adviser who gave a presentation on how technology appraisals will be incorporated into the guideline.

This included details of which technology appraisals will be included and for what review question. The committee were shown an outline of the proposed visual summary and were asked for their input on a few areas.

The Chair thanked KS for their presentation.

5. RQ 2a(ii) (additional imaging tests for differentiating renal masses in adults with suspected renal cell carcinoma):

- **Presentation of clinical evidence**
- **Presentation of health economic evidence**
- **Health equality and inequality considerations**
- **Committee discussion**

The Chair introduced Lina Manounah (LM), Technical Analyst and Lindsay Claxton (LC), Health Economics Adviser who presented the clinical and cost effectiveness evidence for additional imaging tests for differentiating renal masses in adults with suspected renal cell carcinoma. This included evidence on Contrast-Enhanced Ultrasound (CEUS) and single-proton emission computerised tomography (SPECT/CT) using 99mTc-sestamibi.

The committee discussed what was presented and answered specific questions from the NICE team and considered any health equality and health inequality issues in this area.

BS thanked the committee for their input.

6. Recommendation drafting

Taking input from the committee to draft the initial wording, the NICE team were able to draft recommendations and research recommendations for additional imaging tests that would be taken away for further edits.

BS thanked the committee for their input.

7. Next steps and AOB

BS summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, BS brought the meeting to a close.

Date of next meeting: 20/03/2025

Location of next meeting: Virtual